SWOG clinical trial number
SWOG-9228

Evaluation of Interleukin-4 (IL-4) in Disseminated Malignant Melanoma, Phase II

Closed
Phase
Accrual
90%
Published
Abbreviated Title
Evaluation of Interleukin-4 (IL-4) in Disseminated Malignant Melanoma, Phase II
Activated
03/01/1994
Closed
09/01/1995

Research committees

Melanoma

Publication Information Expand/Collapse

2008

Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. [PMID18235113]

EL Korn;PY Liu;SJ Lee;JAW Chapman;D Niedzwiecki;VJ Suman;J Moon;VK Sondak;MB Atkins;EA Eisenhauer;W Parulekar;SN Markovic;S Saxman;JM Kirkwood Journal of Clinical Oncology 26(4):527-534

2001

Gender and other survival predictors in patients with metastatic melanoma on Southwest Oncology Group trials

JM Unger;LE Flaherty;PY Liu;KS Albain;VK Sondak Cancer 91(6):148-1155

1998

Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: A Southwest Oncology Group study.

RP Whitehead;JM Unger;JW Goodwin;MJ Walker;JA Thompson;LE Flaherty;VK Sondak Journal of Immunotherapy 21(6):440-446

1996

Phase II trial of recombinant human interleukin-4 (rhuIL-4) in patients with disseminated malignant melanoma: A Southwest Oncology Group (SWOG) study.

RP Whitehead;J Unger;SP Balcerzak;JW Goodwin;SE Rivkin;LE Flaherty;VK Sondak American Society of Clinical Oncology 15:438(#1363)

Other Clinical Trials

SWOG Clinical Trial Number
S2000

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases
Research Committee(s)
Melanoma
Activated
09/23/2020
Accrual
100%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6174

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma
Research Committee(s)
Melanoma
Activated
10/01/2018
Open
Phase
SWOG Clinical Trial Number
CTSU/EA6141

Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Research Committee(s)
Melanoma
Activated
09/10/2015
Open
Phase